Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 25955104)

  • 1. FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer.
    Peng X; Luo Z; Kang Q; Deng D; Wang Q; Peng H; Wang S; Wei Z
    Cancer Biol Ther; 2015; 16(7):1099-109. PubMed ID: 25955104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Forkhead factor FOXQ1 promotes TGF-β1 expression and induces epithelial-mesenchymal transition.
    Fan DM; Feng XS; Qi PW; Chen YW
    Mol Cell Biochem; 2014 Dec; 397(1-2):179-86. PubMed ID: 25287361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP1-stabilised FOXQ1 promotes ovarian cancer progression by activating the LAMB3/WNT/β-catenin signalling pathway.
    Wu J; Wu Y; Chen S; Guo Q; Shao Y; Liu C; Lin K; Wang S; Zhu J; Chen X; Ju X; Xia L; Wu X
    Oncogene; 2024 Mar; 43(12):866-883. PubMed ID: 38297082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S100A6 mediated epithelial-mesenchymal transition affects chemosensitivity of colorectal cancer to oxaliplatin.
    Zhang C; Zeng M; Xu Y; Huang B; Shi P; Zhu X; Cao Y
    Gene; 2024 Jul; 914():148406. PubMed ID: 38521111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXQ1 promotes the osteogenic differentiation of bone mesenchymal stem cells via Wnt/β-catenin signaling by binding with ANXA2.
    Xiang L; Zheng J; Zhang M; Ai T; Cai B
    Stem Cell Res Ther; 2020 Sep; 11(1):403. PubMed ID: 32943107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A83-01 inhibits TGF-β-induced upregulation of Wnt3 and epithelial to mesenchymal transition in HER2-overexpressing breast cancer cells.
    Wu Y; Tran T; Dwabe S; Sarkissyan M; Kim J; Nava M; Clayton S; Pietras R; Farias-Eisner R; Vadgama JV
    Breast Cancer Res Treat; 2017 Jun; 163(3):449-460. PubMed ID: 28337662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor suppressor p53 is a negative regulator of the carcinoma-associated transcription factor FOXQ1.
    Pizzolato G; Moparthi L; Pagella P; Cantù C; D'Arcy P; Koch S
    J Biol Chem; 2024 Apr; 300(4):107126. PubMed ID: 38432629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear isoform of RAPH1 interacts with FOXQ1 to promote aggressiveness and radioresistance in breast cancer.
    Liu Q; Cao Y; Wei X; Dong H; Cui M; Guan S; Liu B; Wang X; Xing P
    Cell Death Dis; 2023 Dec; 14(12):803. PubMed ID: 38062011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.
    Liu D; Wang W; Wu Y; Qiu Y; Zhang L
    Curr Cancer Drug Targets; 2024; 24(5):519-533. PubMed ID: 38804344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOXQ1 recruits the MLL complex to activate transcription of EMT and promote breast cancer metastasis.
    Mitchell AV; Wu L; James Block C; Zhang M; Hackett J; Craig DB; Chen W; Zhao Y; Zhang B; Dang Y; Zhang X; Zhang S; Wang C; Gibson H; Pile LA; Kidder B; Matherly L; Yang Z; Dou Y; Wu G
    Nat Commun; 2022 Nov; 13(1):6548. PubMed ID: 36319643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead Box Q1 Is Critical to Angiogenesis and Macrophage Recruitment of Colorectal Cancer.
    Tang H; Zheng J; Bai X; Yue KL; Liang JH; Li DY; Wang LP; Wang JL; Guo Q
    Front Oncol; 2020; 10():564298. PubMed ID: 33330033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular functions of microRNAs in colorectal cancer: recent roles in proliferation, angiogenesis, apoptosis, and chemoresistance.
    Ellakwa DE; Mushtaq N; Khan S; Jabbar A; Abdelmalek MA; Wadan AS; Ellakwa TE; Raza A
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Apr; ():. PubMed ID: 38619588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol triggers autophagy-related apoptosis to inhibit the progression of colorectal cancer via inhibition of FOXQ1.
    Zhou M; Niu H; Cui D; Huang G; Li J; Tian H; Xu X; Liang F; Chen R
    Phytother Res; 2024 Jun; 38(6):3218-3239. PubMed ID: 38682953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination.
    Huang D; Du X
    World J Gastroenterol; 2008 Mar; 14(12):1823-7. PubMed ID: 18350618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide mimetic NC114 induces growth arrest by preventing PKCδ activation and FOXM1 nuclear translocation in colorectal cancer cells.
    Taguchi Y; Nakaya T; Aizawa K; Noguchi Y; Maiya N; Iwamoto C; Ohba K; Sugawara M; Murata M; Nagai R; Kano F
    FEBS Open Bio; 2024 Apr; 14(4):695-720. PubMed ID: 38425293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXF1 promotes tumor vessel normalization and prevents lung cancer progression through FZD4.
    Bian F; Goda C; Wang G; Lan YW; Deng Z; Gao W; Acharya A; Reza AA; Gomez-Arroyo J; Merjaneh N; Ren X; Goveia J; Carmeliet P; Kalinichenko VV; Kalin TV
    EMBO Mol Med; 2024 May; 16(5):1063-1090. PubMed ID: 38589650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DDR2 coordinates EMT and metabolic reprogramming as a shared effector of FOXQ1 and SNAI1.
    Mitchell AV; Wu J; Meng F; Dong L; Block CJ; Song WM; Zhang B; Li J; Wu G
    Cancer Res Commun; 2022 Nov; 2(11):1388-1403. PubMed ID: 36713812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HNRNPA2B1 promotes oral squamous cell carcinogenesis via m
    Wang X; Zhi M; Zhao W; Deng J
    IUBMB Life; 2024 Jan; ():. PubMed ID: 38265150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in CCK2R alter receptor activity that promote oncogenic phenotypes.
    Willard MD; Lajiness ME; Wulur IH; Feng B; Swearingen ML; Uhlik MT; Kinzler KW; Velculescu VE; Sjöblom T; Markowitz SD; Powell SM; Vogelstein B; Barber TD
    Mol Cancer Res; 2012 Jun; 10(6):739-49. PubMed ID: 22516348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies.
    Tortolina L; Duffy DJ; Maffei M; Castagnino N; Carmody AM; Kolch W; Kholodenko BN; De Ambrosi C; Barla A; Biganzoli EM; Nencioni A; Patrone F; Ballestrero A; Zoppoli G; Verri A; Parodi S
    Oncotarget; 2015 Mar; 6(7):5041-58. PubMed ID: 25671297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.